Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12284024 | 1.00 | MGLL (0.51) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL26519953 | 0.97 | MGLL (0.49) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL18893611 | 0.95 | MGLL (0.46) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL17637534 | 0.94 | PTGS1 (0.48) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL18264898 | 0.94 | MGLL (0.46) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL26331966 | 0.93 | SMN1; SMN2 (0.51) | MGLLPOLBHSD17B10SMN1; SMN2TSHR | |
| SCHEMBL12628920 | 0.93 | TSHR (0.49) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL17813301 | 0.93 | MGLL (0.44) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL24383845 | 0.92 | MGLL (0.44) | MGLLPOLBHSD17B10PTGS1PTGS2 | |
| SCHEMBL6727204 | 0.92 | MGLL (0.42) | MGLLPOLBHSD17B10PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | PROTAGONIST THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20200239523-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20180148477-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | PROTAGONIST THERAPEUTICS, INC. | 2018-04-19 | — | — | US | disclosed |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2017-11-16 | — | — | US | disclosed |
| US-9809623-B2 | α4β7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809623-B2 | α4β7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| WO-2017165676-A1 | METHODS FOR SYNTHESIZING α4β7 PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| US-9714270-B2 | a4B7 integrin thioether peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9714270-B2 | a4B7 integrin thioether peptide antagonists | PROTAGONIST THERAPEUTICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9518091-B2 | A4B7 peptide monomer and dimer antagonists | PROTAGONIST THERAPEUTICS, INC. | 2016-12-13 | — | — | US | disclosed |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-09 | — | — | US | disclosed |
| US-20160152664-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160152664-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | PROTAGONIST THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031944-A1 | a4B7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS | ITGB7, EPCAM, ITGB4 | MGLL 4780/4885POLB 4327/4885HSD17B10 3886/4885 |
| US-20160159862-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | MGLL 4593/4885POLB 4300/4885HSD17B10 3977/4885 |
| US-20180105572-A1 | NOVEL CYCLIC MONOMER AND DIMER PEPTIDES HAVING INTEGRIN ANTAGONIST ACTIVITY | VCAM1, EPCAM, ICAM1 | MGLL 4365/4885POLB 4155/4885HSD17B10 4476/4885 |
| US-20230063321-A1 | Methods for Treating Inflammatory Bowel Diseases with alpha4beta7 Integrin Antagonists | ITGB7, ITGB4, ITGA4 | MGLL 4633/4885POLB 4383/4885HSD17B10 3626/4885 |
| US-20200239523-A1 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ITGB7, EPB41 | MGLL 4780/4885POLB 4436/4885HSD17B10 3718/4885 |
| US-11840581-B2 | α4β7 thioether peptide dimer antagonists | EPCAM, SELPLG, VCAM1 | MGLL 4530/4885POLB 4489/4885HSD17B10 4098/4885 |
| US-20160152664-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | MGLL 4593/4885POLB 4300/4885HSD17B10 3977/4885 |
| US-20240209026-A1 | A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | EPCAM, ANXA7, GRB7 | MGLL 4647/4885POLB 4434/4885HSD17B10 3528/4885 |
| US-20170327541-A1 | METHODS FOR SYNTHESIZING alpha4ß7 PEPTIDE ANTAGONISTS | PSMA7, PSMA4, IL4 | MGLL 4882/4885POLB 2290/4885HSD17B10 4420/4885 |
| US-20180148477-A1 | NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS | EPCAM, VCAM1, ITGB7 | MGLL 4593/4885POLB 4300/4885HSD17B10 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.